CADILA HEALTHCARE LTD. - 532321 - Audited Financia l Results For The Quarter / Year Ended On March 31, 2019.
Audited Financial Results for the quarter / year ended on March 31, 2019.29-05-2019
29-05-2019
CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives final approval from the USFDA for Esomeprazole Magnesium Delayed-Release Capsules USP23-05-2019
Cadila Healthcare Ltd - 532321 - Format of Initial Disclosure to be made by an entity identified as a Large Corporate
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompayCADILA HEALTHCARE LTD. 2CINL24230GJ1995PLC025878 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 3.00 4Highest Credit Rating during the previous FY AA+ 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)CRISIL LTD. 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkNSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Dhaval N. Soni Designation: Company Secretary EmailId: dhavalsoni@zyduscadila.com Name of the Chief Financial Officer: Nitin D. Parekh Designation: Chief Financial Officer EmailId: nitinparekh@zyduscadila.com Date: 21/05/2019 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.21-05-2019
CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
The Company has planned investor interaction through a conference call on May 29, 2019 at 4:30 p.m., post announcement of audited financial results for the quarter / year ended on March 31, 2019.21-05-2019
Cadila Healthcare Ltd - 532321 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Details of loss of certificate / duplicate certificate20-05-2019
Cadila Healthcare Ltd - 532321 - Board Meeting Intimation for Dividend And Annual Audited Financial Results
CADILA HEALTHCARE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2019 ,inter alia, to consider and approve Dividend and Annual Audited Financial Results17-05-2019
What's bugging Indian, Chinese medicine companies making crucial heart drug
US inspectors cite Cadila Healthcare and Alkem Laboratories--both makers of valsartan--for quality-control failures.16-05-2019
Cadila Healthcare Ltd - 532321 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Details of loss of share certificate / duplicate certificate16-05-2019
Zydus among generic companies facing lawsuit by US states: Cadila
Drug firm, Cadila Healthcare, on Tuesday, announced that Zydus Pharmaceuticals Inc, is included in the lawsuit filed against some generic companies by14-05-2019